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Abstract
The midbrain dopaminergic (mDA) neurons of the substantia nigra and the ventral tegmental area
play a fundamental role in the control of voluntary movement and the regulation of emotion, and
are severely affected in Parkinson's disease. Recent advances in mouse genetics and vertebrate
development have provided us with insight into the genetic cascades involved in the development
of mDA neurons, including the induction of mDA neuron progenitors in the ventral
mesencephalon, the specification of the mDA neuronal fate and the maintenance of postmitotic
mDA neurons. In parallel, rapid progress has been made in the generation of DA neurons from
pluripotent stem cells and the development of stem cell-based therapies for Parkinson's disease.
Here, we summarize the new findings via the developmental progression of mDA neurons and
outline how this knowledge has been exploited to develop novel paradigms for the in vitro
generation of these neurons from embryonic stem cells.
Introduction
Dopamine containing neurons are present in different
positions in the vertebrate central nervous system with the
largest assembly in the midbrain. Midbrain dopaminergic
(mDA) neurons are separated into functionally distinct
subgroups called the substantia nigra compacta (SNc
(also called the A9 group) and the ventral tegmental area
(VTA (also called the A10 group) based on their position
within the midbrain and the target structures which they
innervate [1]. Dopaminergic neurons of the SNc primarily
project to the dorsolateral striatum and regulate motor
function. The VTA neurons, on the other hand, project to
the ventromedial striatum, cortical areas and the limbic
system and are involved in emotional behaviour and
mechanisms of natural motivation and reward. In
humans, the preferential degeneration of SNc neurons
results in Parkinson's disease whilst defects of the VTA
neuron system are implicated in psychiatric disorders.
Because of their involvement in Parkinson's disease and
other mental disorders, mDA neurons have been a focus
of clinical interest and a subject of intensive studies for a
long time. For Parkinson's disease, a potential therapy is
to replace the lost mDA neurons with healthy DA neurons
that have been generated in vitro through the differentia-
tion of stem cells. To achieve this, a comprehensive under-
standing of the genetic cues and extrinsic signalling
cascade controlling the fate choice of pluripotent embry-
onic stem (ES) cells into neuroepithelial stem cells and
subsequently into functional midbrain specific DA neu-
rons is required. In this regard, recent studies have identi-
fied a number of regulatory factors that influence the
Published: 30 September 2008
Molecular Brain 2008, 1:8 doi:10.1186/1756-6606-1-8
Received: 2 June 2008
Accepted: 30 September 2008
This article is available from: http://www.molecularbrain.com/content/1/1/8
© 2008 Gale and Li; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
Page 2 of 10
(page number not for citation purposes)
emergence of mDA neurons during vertebrate embryo-
genesis. These studies not only have increased our under-
standing of mDA neuron development in vivo, they have
also guided the development of new paradigms for the in
vitro generation of mDA neurons from ES cells. In return,
ES cell differentiation in vitro provides a powerful
research tool for the genetic dissection of mDA neuron
development and cell biology.
Several excellent reviews have extensively analyzed the
extrinsic signalling pathways and genetic programme gov-
erning mDA neuronal differentiation and functional mat-
uration [2-7]. In this article we summarise insights from
recent studies of mDA neuron fate specification in animal
models, highlighting the pivotal role of fundamental
developmental studies in devising novel strategies har-
nessing ES cell differentiation to produce the mDA neuro-
nal phenotype.
From epiblast to midbrain DA neurons
In the embryo, the pluripotent cells of the epiblast give
rise to the multitude of different cell types of the adult ani-
mal. A complex series of extracellular signals and cell
autonomous differentiation events transform these cells
through germ layer specification, regionalisation and
finally cell specific determination. In the generation of
neurons of the SNc, research has focused on three major
transitions: regionalisation of the neural plate, midbrain
cell fate determination and finally terminal differentia-
tion into mDA neurons (Figure 1). Differentiation of epi-
blast cells in culture into dopaminergic neurons parallels
this pathway and knowledge gained from one system con-
tributing to research in the other.
Midbrain Regionalisation
Regionalisation begins early in neural plate development.
At its inception the neural plate is axially defined: ante-
rior-posterior and dorsal-ventral. The lateral edges of the
neural plate roll up during neuralation becoming dorsal
in the newly created tube. The neural plate midline
becomes the ventral-most part of the developing nervous
system. This positions the midline cells to receive extrinsic
signals from the underlying mesoderm as well as signal-
ling factors from within the neural plate (Figure 1 Region-
alisation). During the establishment of regional identity
the anterior neural tube develops a morphological con-
striction that co-localises with the boundary that defines
and instructs cell fate restriction: the midbrain hindbrain
border (MHB). The MHB, in conjunction with extrinsic
signals from the mesoderm and endogenous regional pat-
terning genes, specifies tightly localised populations of
neural tissue in the flanking midbrain and hindbrain ter-
ritories. The regional specification of the midbrain estab-
lishes a molecular identity that potentiates the cells of the
ventral midbrain neuroepithelium to respond to subse-
quent dopaminergic fate determining signals.
The axial position of the MHB is established and main-
tained by Fgf8 expression and the co-repressive interac-
tions of Otx2 and Gbx2 [8-11]. MHB signalling genes,
Wnt1 and Engrailed 1 and Engrailed 2 (En1/2) are
required for proliferation and survival of the ventral mid-
brain cells and Fgf8 is an instructive signal required for
mDA neuron determination [3,12,13] (Figure 1 Regional-
isation). In addition, Wnt1 mutant mice showed a loss of
the mDA neuronal transcription factor Pitx3 expression in
the Th+ cell population. Although Fgf8 is not expressed in
the midbrain, it clearly plays an extrinsic role in defining
midbrain cell fate. Its ability to generate ectopic mDA neu-
rons from naïve forebrain tissue has been shown and the
blockage of FGF signalling results in a loss of mDA neu-
rons [3,13]. Since Fgf8 can induce Wnt1 expression it is
not clear if Fgf8 acts directly on mDA neuron progenitor
populations or through induction of Wnt1 [14].
Along with Fgf8 and Wnt1, Shh and Otx2 are required for
specification of the midbrain region [15-17]. Interference
with Shh or Otx2 signalling results in malformation or
absence of the midbrain. The midbrain of the Shh mutant
is reduced in size, has extensive patterning defects and
contains no Th+ cells [18]. In the Otx1/2 double mutant,
the entire head including the midbrain is absent. More
informative for the study of midbrain development was
the discovery that a subtle shifting of Otx2's caudal expres-
sion boundary effects mDA neuron population size; a cau-
dal shift results in an increase in population and a rostral
one a reduction [19-21]. This increase or decrease is
inversely reflected in a change in the seratonergic popula-
tion, the ventral neuronal population of rostral hind-
brain. These results demonstrate an Otx2 regulation of
midbrain size but more importantly the switch from
dopaminergic to seratonergic fate illustrates the change in
regional identity controlled by Otx2 expression [22]. The
ventral midbrain is also uniquely affected by Shh. Shh
patterns ventral neuronal fate in the brain and the spinal
cord but it is only ventral cells with the regional identity
of the midbrain that respond to Shh expression by acquir-
ing a dopaminergic cell fate [23-25].
In the spinal cord, the dorsal-ventral pattern of combina-
torial and mutually exclusive areas of gene expression that
determine the neural subtype is well established [26,27].
The pattern is initiated by Shh expression being induced
in the floor plate cells, the ventral midline, by extrinsic
Shh signalling from the underlying notochord. In the
midbrain, this creates a signalling centre that, in combina-
tion with Otx2, sets up a regionally specific dorsoventral
pattern of gene expression. Electroporation of Shh later-
ally, in the midbrain, induces a dorsally shifted archateMolecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
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pattern of expression of midbrain neuronal cell fate mark-
ers [28]. More dramatically a small point of ectopic Shh
expression in the lateral midbrain generates a miniature
series of bands of molecular markers duplicate to those
that flank the endogenous midline [28].
Shh through binding its receptor, patched, derepresses
smoothened to initiate a signalling cascade that eventu-
ally converges on the Gli family of transcription factors
[15,29]. Dissection of the Shh signalling pathway in the
midbrain points to a Gli2A-mediated control of floor
plate Shh induction prior to E9 [23]. A second cascade ini-
Schematics of the key players of mDA neuron development Figure 1
Schematics of the key players of mDA neuron development. Regionalisation of the neural tube (hindbrain (hb) brown, 
midbrain (mb) pink) establishes midbrain tissue identity via the inductive signals of Shh and Fgf8, which arise from the noto-
chord (grey circle) and the midbrain-hindbrain border (blue) respectively, combined with Otx2 expression. This interaction 
enables midbrain ventral midline cells to respond to the later expression of the mDA neuron determination gene Lmx1a. Spec-
ification of the mDA neuronal identity occurs within the proliferative zone (grey) of the ventral midline. Here, Msx1 and Foxa2 
promote generic neurogenesis via regulation of Ngn2 whilst Lmx1a, supported by Msx1, specifies mDA neuron cell fate. As 
these mDA neuron progenitors become postmitotic and enter the intermediate zone (yellow), they begin to express the pan 
neuronal marker Tuj1 and, subsequently, the DA neuron transmitter regulator, Nurr1. Lmx1b and Wnt1 positively control 
early Pitx3 expression in some Nurr1+ cells. The last stage in mDA neuronal differentiation proceeds as the Pitx3+ cells and the 
Th+ cells migrate ventrally into the peripheral zone (red). The ventrolaterally located Pitx3+Th- cell subpopulations coalesce 
leaving a Pitx3- Th+ cell group in a medial position. Eventually, the early Pitx3 expressing subpopulation migrates laterally to 
make up the neural population of the SNc and begin to express Th. The remaining medial, Th+, cells form the VTA. All Nurr1+ 
cells come to express Th and Pitx3. En1 and En2 maintain survival of the mature mDA neurons in the ventral midbrain. [Col-
ours highlight the postulated region of activity of the genes in the corresponding colour.]Molecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
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tiated by Shh signalling represses ventral midbrain cell
death resulting from cleavage of Gli3. The complete loss
of Gli2A results in a severe reduction in mDA neurons and
absence of Isl1+ cells and Nkx2.2+ cells, the more lateral
ventral midbrain neuronal subtypes. The loss of Gli2A
expression at E9 results in only a moderate decrease in the
mDA neurons population but, again, a complete absence
of the Isl1+ and Nkx2.2+ neurons [23]. By E11.5, neither
the Gli2A-mediated Shh signalling nor the expression of
Shh itself is required for normal development of the ven-
tral midbrain neuron populations. [23,30] This suggests
Shh expression in the midbrain neuroepithelium specifies
the mDA neuron progenitor population shortly after Shh
induction but more prolonged signalling is necessary to
establish more lateral neuronal identity. Expression is
restricted to the floor plate and patterning is affected in
lateral tissue therefore this signalling acts over many cell
diameters distance [15]. Shh signalling from the floor
plate seems to generate a cascade of cell differentiation
events requiring no further extrinsic instructive signals
that result in the pattern of the neural phenotypes of the
ventral midbrain.
Recent work with conditional mutants precisely targeted
to dissect the spatial regulatory activities of Otx2 has
greatly broadened our understanding of the gene interac-
tions necessary to create the midbrain dorsoventral pat-
tern of neuronal fates [17,31,32]. Otx2  is normally
expressed in all midbrain cells. Driving Otx2 expression
by the Otx1 regulatory region results in a loss of lateral
Otx2 expression and a lateral expansion of the Shh expres-
sion region [32]. Normally, Shh is expressed only in the
most ventral population, which give rise to the mDA neu-
rons, flanked by a Nkx6.1+ region, which generates the red
nucleus (RN) progenitors, more lateral is the Nkx2.2
expressing region and the dorsal cells express Pax3. Coor-
dinated with the induction of a broader Shh domain is a
dorsal shift of the Nkx6.1 and Nkx2.2 expressing regions
and a reduction of the Pax3 region. This change in the dor-
soventral pattern leads to an increase in mDA neurons
and a loss of RN neurons. A second mutant, regulating
Otx2 expression using the En1 promoter, produces a loss
of both ventral and lateral Otx2 expression [31]. The out-
come of this manipulation was a similar lateral expansion
of Shh, a dorsal shift in Nkx6.1 expression and a dorsal
reduction of the Pax expressing region but in this case the
Nkx2.2 expanded ventrally into the normal Shh expressing
territory. In contrast to the previous result, the combined
loss of ventral and lateral Otx2  midbrain expression
causes a severe reduction in mDA neurons. These experi-
ments indicate that endogenous lateral Otx2 expression
maintains Shh in its ventral domain preventing the Shh
inhibition of Nkx6.1. Additionally, Otx2 represses ventral
expression of Nkx2.2, which can inhibit mDA neuronal
differentiation
Fgf8, Shh and Otx2, genes involved in the early regional
specification, are capable of promoting dopaminergic cell
specification in greater abundance in their normal loca-
tion as well as ectopically in naïve hindbrain or forebrain
tissue [13,21,25,28,32]. The genes involved with subse-
quent determination, such as Lmx1a, also required for
dopaminergic differentiation, are limited in their induc-
tive powers to increasing the population of mDA neurons
only in the midbrain [24]. This reflects the decreasing
plasticity of the developing nervous tissue as it progresses
through cell fate determination.
Dopaminergic fate determination
The last few years have been rich in data contributing to
understanding of the interactive molecular cascade
involved in the multi-step differentiation of the mDA neu-
ron progenitor population as well as identifying key play-
ers: Lmx1a, Ngn2, Fox2a, and Shh [23,24,29,30,33,34].
As the neuroepithelium of the midbrain develops, it thick-
ens by cell proliferation and becomes layered. The cells in
a narrow band adjacent to the ventricle retain their prolif-
erative neural stem cell properties while other cells move
out of this proliferative zone, exit the cell cycle and begin
to differentiate. The mDA neuron progenitors inhabit the
ventral most proliferative zone and move ventrally and
then laterally as they differentiate (Figure 1 Specification).
These cells express Lmx1a, Foxa2, Lmx1b, Msx1/2, Ngn2
and, at early stages, Shh. Cells at this stage acquire mDA
neuronal specification and begin the final steps of postmi-
totic differentiation. They begin to express Nurr1 as well
as the mDA neuron specific molecule, Pitx3, in the inter-
mediate zone, which is ventral to the proliferative zone.
As they reach the ventral peripheral edge of the neuroepi-
thelium, they are fully differentiated mDA neurons and
express Th (Figure 1 Differentiation) [5].
The genes expressed in the ventral proliferative zone have
highly interactive regulatory mechanisms. Lmx1a, Foxa2,
Ngn2, Lmx1b, Msx1/2, and Shh have all been shown to be
necessary for normal mDA neuron development but of
them only Shh and Lmx1a are both necessary and suffi-
cient to induce mDA neurons [24]. The data on Shh par-
ticipation in midbrain patterning has been discussed in
the previous section. Two different studies have indicated
that Shh is required only prior to E10.5 in mDA neuron
determination and mDA neuron progenitor cells continue
to be born after Shh is downregulated in the ventral mid-
brain [23,30]. Lmx1a, on the other hand, is continually
expressed during mDA neuron progenitor production
[35]. Silencing Lmx1a in the developing midbrain with
siRNA results in a dramatic reduction in Nurr1+  cells
whilst its ectopic expression results in an expansion of the
Nurr1  expressing midbrain region [24]. These data, in
combination with Shh's ability to induce firstly Lmx1a
and subsequently Th in naïve midbrain explants, indicatesMolecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
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that Shh promotes production of mDA neurons through
induction of Lmx1a [24]. Shh also is capable of regulating
Foxa2 expression which in turn positively regulates Ngn2
expression (Figure 1)[30,32]. Interestingly, Foxa2  is
required for normal Nurr1 expression from E10.5, the end
point of Shh participation [30]. Ngn2 is also upregulated
by Msx1/2 which can be induced by Lmx1a overexpres-
sion in midbrain tissue [24].
The transition of a cell from the proliferative zone to the
intermediate zone is mediated by Ngn2. Loss of function
mutation of Ngn2  dramatically delays and reduces the
number of Nurr1+ cells in the intermediate zone and does
so in a dose dependent manner [32-34]. Compound dele-
tion of the Ngn1 and Ngn2 alleles increases the severity of
this reduction [30,34]. The involvement of Ngn2 in neu-
rogenesis is highlighted by the decrease in both total
number of cells and number of neurons in the mutant
intermediate zone [30,33,34]. The decrease of cell
number is not associated with apoptosis but instead with
a reduction in Hes5 and Dll1expression, markers of prone-
ural activity the ventricular zone [34]. Therefore, the cell
loss is likely to be the result of a retardation of the rate of
ventricular zone to intermediate zone transition. In the
Ngn2 mutants, depleted Nurr1+ population do express Th
and there is some recovery of the Nurr1+ population dur-
ing development. This presents the possibility of an
Ngn2-independent pathway of mDA neuron differentia-
tion. There is evidence that in the mutant state Mash1 can
compensate for the loss of Ngn2 but since the deletion of
Mash1 in normal embryos has no effect on mDA neuron
development it is probable that Ngn2 is the normal medi-
ator of neurogenesis [34]. Using Ngn2-GFP mice, Thomp-
son et al were able to demonstrate that all mDA neurons
were derived from Ngn2-GFP+ cells both in culture and in
the recipient striatum following transplantation [36].
Msx1 is also expressed in the proliferative zone. While
Msx1 can not induce Lmxla, it does act synergistically with
Lmx1a to promote the mDA neuron progenitor popula-
tion through inhibition of Nkx6.1 on the lateral edges of
the ventral proliferative zone [24]. This inhibition results
in Ngn2 expression in those areas. In the absence of
Lmx1a, the Msx1-mediated Ngn2 expression does not
result in the induction of Nurr1 [24]. This demonstrates
the need for pre-specification of the Ngn2+ proliferating
cells by Lmx1a to determine the mDA neuron phenotype
(Figure 1 Specification).
Terminal differentiation
The final step in the differentiation of dopaminergic neu-
rons is the expression of Th, the rate limiting enzyme in
the production of dopamine. Th expression is not initi-
ated in mDA neurons of Nurr1  null embryos [37-39].
However, the mDA neuronal lineage is properly specified
as demonstrated by the expression Pitx3 and Aldh1a1 at
the appropriate stages in the ventral midbrain of Nurr1
mutant mice. Therefore, Nurr1 controls the dopaminergic
neuron transmitter phenotype but does not play a role in
the specification of mDA neurons. Recently it has been
shown that Nurr1 regulates Th by activating the NGF-1
response element in the Th promoter region after its own
phosphorylation by ERK1/2 [40,41]. Furthermore, the
onset of Parkinson's disease parallels the interruption of
this interaction [40].
Another transcription factor implicated in the regulation
of Th and the proper differentiation of a subset of mDA
neurons is the paired-like homeodomain protein Pitx3.
Pitx3 is expressed in both the SNc and the VTA DA neu-
rons [42,43]. However, lack of Pitx3 results in the prefer-
ential loss of the SNc neuronal sub-population whereas
the VTA neurons are relatively intact, a phenotype that
closely resemble that of Parkinson's disease [44-47]. Fur-
thermore, analysis of the Pitx3-GFP knockin mice
revealed a restricted down-regulation of Th in the SNc
cells prior to their death [47]. The preferential cell loss is
closely linked with the segregation of Pitx3 expression in
two apparently discrete mDA neuron precursor cell popu-
lations during the onset of terminal mDA neuron differ-
entiation. Cells located at the ventrolateral position of the
marginal zone express Pitx3 prior to Th whilst cells posi-
tioned dorsomedially express Th before Pitx3 [47]. It is
thought that the ventrolateral cells go on to form the SNc
whilst those more medial become the VTA. The differen-
tial regulation of Pitx3 in SNc dopaminergic precursor
cells dictates their strict dependence on Pitx3 for survival.
The heterogeneity of the mDA neuron population and
their differential dependence on Pitx3 has been further
demonstrated by the identification of Aldh1a1, a retinoic
acid synthesising enzyme, as a SNc specific Pitx3 target
gene and the partial rescue of Pitx3 deficient phenotype by
retinoic acid [48].
Finally, the En1 and En2 homeobox transcription factors
are required for the maintenance of the mDA neurons in
late stages of foetal development and in the adulthood. In
the En1/2 double mutants all mDA neurons die between
E12, the onset of En1 expression, and E14 [49]. While the
En1+/-; En2-/- mutant has the normal mDA neuronal com-
pliment at birth, it then begins to loose Th+ neurons in the
SNc while retaining those of the VTA [50]. These results
indicate that En1 is required for mDA neuron mainte-
nance and, more specifically, highlight the distinct sur-
vival requirements of SNc and VTA neurons.
Steering ES cell differentiation into a DA fate
It is generally accepted that much of ES cell differentiation
in vitro mimics vertebrate development as described
above. Therefore, induction of a specific cell fate shouldMolecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
Page 6 of 10
(page number not for citation purposes)
involve the application of known extracellular factors in a
stepwise manner during the course of ES cell differentia-
tion. The aim is to induce a cascade of transcription
resembling normal development. Indeed, most differenti-
ation paradigms reported to date apply Shh and FGF8 to
differentiating ES cell cultures [51-57]. A panel of survival-
promoting factors including glial cell line-derived neuro-
trophic factor, neurturin, transforming growth factor-β3
and dibutyryl-cAMP have been shown to promote the
maturation and survival of ES cell-derived Th+ neurons
[58]. Furthermore, foetal midbrain astrocytes can pro-
mote the production of DA neurons from ES cells [59].
Induction with Shh and FGF8 during ES cell differentia-
tion can result in a culture in which ~30% of the neuronal
population expresses Th. In these studies Shh and FGF8
are applied at the time when neural progenitor produc-
tion (ie. Nestin+, Sox1+ cells) is at its peak. This is based on
the understanding, supported by developmental studies,
that Shh induces a DA fate via acting on ES cell derived
Nestin+ Sox1+ neural progenitors. However, we found that
Shh and FGF8 were unable to stimulate more DA neurons
in FACS (fluorescence activated cell sorting) purified
Sox1+ neural progenitors than observed in un-sorted con-
trol cultures [60]. This finding indicates that DA induction
occurred in 'primitive' neural progenitors prior to or at the
point of Sox1 expression in differentiating ES cells.
DA neurons can also be efficiently induced by stromal
cell-derived inducing activity (SDIA) produced by bone
marrow derived PA6 stromal cells [61]. This protocol,
which involves culturing ES cells on a layer of PA6 cells,
can generate a high proportion of Th-positive neurons
comparable to those derived through Shh induction as
discussed above. Although the nature of SDIA remains
unclear, it was suggested that SDIA might be a secreted
factor that is secondarily tethered to the cell surface. A
recent study implicates Wnt5 as a component of SDIA
[62]. Co-culture of FACS purified Sox1+ neural progeni-
tors with PA6 did not yield proportionally more
dopaminergic neurons as compared to cultures on poly-
lysine and laminin, suggesting that SDIA mediated DA
induction also occurs at pre-Sox1 expression stage [60].
However, SDIA has a generic promoting effect on the pro-
liferation and survival of foetal and ES cell-derived neural
progenitors ([63], authors unpublished observation).
To date, the most efficient production of dopaminergic
neurons from ES cells is achieved via genetic manipula-
tion of transcription factors that are normally active in
midbrain DA neurons [24,47,64-67]. Nurr1 is able to
induce Th expression in central nervous system precursors
derived from cortex, midbrain tissue, the lateral gangli-
onic eminence and from ES cells [46,64,67-71]. In Nurr1
expressing cultures, enhanced production of Th-positive
neurons was associated with an increase in the expression
level of AADC, DAT, VMAT, and Pitx3. However, engi-
neered Nurr1 also induces Th expression in ES cell derived
non-neuronal progeny [72]. This indicates that, consistent
with mouse genetic studies, Nurr1 controls Th expression
independent of their neuronal cell fate specification [37].
Regional (midbrain) identity of ES cell-derived 
DA neurons
The pathological hallmark of Parkinson's disease is the
preferential loss of the substantia nigra subgroup of mDA
neurons. Previous transplantation studies demonstrated
that only midbrain dopaminergic cells are therapeutically
useful in cell replacement therapy in animal models of
Parkinson's disease [73]. Furthermore, transplanted DA
neurons that form synaptic connections with the host
striatum exhibit characteristics of the substantia nigra
neurons demonstrated by morphology and the expression
of Girk2 (a marker that is preferentially expressed by adult
nigral neurons) [36]. Therefore, cells to be developed with
Parkinson's disease therapy in mind must possess the
capacity to generate mDA neurons, ideally those of sub-
stantia nigral character.
With increasing recognition of the necessity of generating
DA neurons of 'true' midbrain property, many recent
studies have investigated the induction, in ES cell derived
neuronal cultures, of midbrain neural progenitor markers
(e.g. Pax2, En1, Lmx1a) and the generation of midbrain
specific post mitotic DA neurons (Pitx3+, Aldh1+) either
by RT-PCR or immunocytochemistry [24,43,65,74-76].
The homeobox protein Pitx3 is the most specific mDA
neuronal marker known to date, due to its exclusive
expression in mDA neurons and their postmitotic precur-
sors [42,43]. The authors have previously generated Pitx3-
GFP knock-in ES cells as a tool for tracking mDA neuron
differentiation in vitro [43]. ES cell derived Pitx3-GFP+
neurons co-express almost completely with known mid-
brain DA markers including Pitx3, engrailed, Lmx1a,
Raldh1 (Ahd2), Nurr1 and pan-DA neuron markers such
as AADC, VMAT2 and Th [43,47,77]. However, only
~15% of SDIA induced ES cell-derived Th+DAT+ neurons
were Pitx3-GFP+, demonstrating that ES cell-derived DA
neurons are heterogeneous and do not all exhibit mid-
brain identity [43]. Similarly, human ES cells also gener-
ate DA neurons of different regional identity [78]. More
recent work with mouse ES cells showed a lack of mDA
specific neuronal marker expression in Th+  neurons
derived using a monolayer differentiation protocol
[24,60,79] whilst an embryoid body based protocol gave
rise to cultures with a high proportion of Th+ neurons
expressing Pitx3-GFP [77]. Shh was applied in both the
monolayer and embryoid body differentiation paradigms
so the varied efficiency in generating midbrain-specific
DA neurons does not seem to be due to limited Shh sig-Molecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
Page 7 of 10
(page number not for citation purposes)
nalling. On the other hand, PA6-co-culture and embryoid
body based ES cell differentiation protocols share a com-
mon feature: high local cell density at neural fate transi-
tion stage. In contrast, efficient monolayer neural
differentiation entails low cell density. Together, these
studies suggest that close cell-cell interaction is necessary
for induction of mDA neuron phenotype.
Consistent with its role in mDA neuron ontogeny, expres-
sion of the Pitx3 transgene in mouse ES cells can promote
the generation of Th+Nurr1+DA neurons co-expressing a
panel of midbrain markers such as En1, Ahd2 and endog-
enous Pitx3. In contrast to Nurr1 overexpression, Pitx3
manipulation does not result in a significant increase in
the overall number of Th+ cells [47,65]. These findings
reinforce the concept of parallel transcription machinery
for DA neural transmitter phenotype and for midbrain DA
neuronal identity [80]. Indeed the combined transduction
of Pitx3 and Nurr1 virus lead to an increase in Th and Dat
RNA expression in neural differentiated human ES cells
[66]. However, a synergistic effect between these two fac-
tors on Th expression was not observed in mouse ES cells
in the same study. Recently, Lmx1a and Msx1 have been
shown as potent stimulators of Pitx3+En1+ DA neuron
generation from mouse ES cells [24]. The effect of Lmx1a
requires prior Shh potentiation so exogenous supply of
Shh during ES cell differentiation is needed. Msx1 can
only induce Th+ neuron production when it is co-trans-
fected with an Lmx1a vector. However, transduction of
Lmx1a, Msx1 and/or Pitx3 virus in cultured rat mesen-
cephalic neural progenitors, alone or combined, did not
increase the number of Th+  cells [81]. Interestingly,
another study observed an enhancement of Th+ neuron
differentiation following the co-culture of Pitx3 trans-
fected rat neurosphere neural progenitors with foetal ven-
tral mesencephalic tissues [82]. Together these studies
suggest that the intact ventral mesencephalic tissue and
differentiating ES cell cultures contain additional instruc-
tive molecules and/or exhibit intrinsic characteristics nec-
essary for dopaminergic neuron determination.
Making DA neurons from neural stem cells
Although all available evidence demonstrates that ES cells
have a greater capacity to produce dopaminergic neurons
than neural stem cells (NSC) or other types of lineage-spe-
cific stem cells [52,83], for cell therapy, it may be prefera-
ble to derive DA neurons from neural stem cells (NSC).
The advantages of using NSC over ES cells are two fold.
Firstly, as a cell type already restricted to the neural line-
age, NSC do not generate teratoma, a multilineage
tumour originating from residual undifferentiated ES cells
following transplantation [69,84]. The formation of ter-
atomas in ES cell transplant is not only unacceptable for
clinical applications, these tumour formations signifi-
cantly compromise the health of the recipients and thus
has hindered long term follow up behaviour analysis of
grafted animals. Secondly, NSC can be derived from foetal
and adult brains, thus one could envisage the potential
use of a patient's own NSC in cell therapy to avoid
immune rejection.
NSC can be routinely established by propagating foetal or
adult neural tissues and ES cell derived neural progenitors
in chemically defined culture media in the presence of
FGF and EGF. However, whether propagated adherently
or as cell aggregates (neurospheres), FGF and EGF
expanded NSC primarily give rise to GABAergic neurons
with no apparent regional identity [85-87]. This may be
attributed to the deregulated dorsoventral patterning of
neural progenitors by FGF during in vitro expansion [88].
The potential of NSC as a therapeutic reagent relies on our
ability to maintain its full neurogenic competence. Using
the human ES cell differentiation model, two recent stud-
ies identified a primitive NSC stage from which a broader
spectrum of neuronal subtypes (including dopaminergic
neurons) can be produced [76,89]. These primitive NSC
are present at very early stage of ES cell neuralisation prior
to FGF/EGF expansion and express similar molecular
markers with that of early anterior neural epithelial cells.
Morphologically, these primitive NSC assemble them-
selves as neural rosette and/or neural tube structures and
were indeed termed as rosette neural stem cells (referred
as R-NSC) by Elkabetz et al., [76]. These authors showed
that Shh and Notch signalling, together with a high den-
sity culture environment, can prolong the maintenance of
the rosette morphology. In contrast, FGF and EGF main-
tained NSC do not display rosette features and show a
greater preponderance of GABAergic neuronal fate. Future
work should address whether the maintenance of neural
rosette morphology by Notch and Shh indeed is coupled
with the maintenance of the neurogenic potency of R-
NSC.
Elucidation of the transcription programme associated
with R-NSC status may lead to the discovery of master reg-
ulators governing NSC potency. A list of candidate marker
genes has been identified by transcriptome profiling for
the primitive NSC and R-NSC [76,89]. Regulated expres-
sion of some of these molecules may be key to preserving
the full neurogenic repertoire of NSC. The identification
of primitive NSC master regulators may offer the means to
re-programme FGF/EGF expanded NSC back to a stage
resembling early anterior neuroepithelium, in a fashion
analogous to the generation of induced pluripotent stem
(iPS) cells.
A similar approach may be taken to program dopaminer-
gic competent NSC by exploiting transcription factors
known to act in this specific neuronal lineage. For exam-
ple, combined gene manipulation of Nurr1 (controllingMolecular Brain 2008, 1:8 http://www.molecularbrain.com/content/1/1/8
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dopaminergic neurotransmitter phenotype) with Lmx1a
or components of the Wnt/Lmx1b-Pitx3 pathway (mid-
brain identity, Figure 1) might be able to impose a mid-
brain DA potential in FGF/EGF expanded NSC.
One should note that for clinical consideration, it is desir-
able to produce the therapeutically important somatic cell
types using extrinsic growth factors or small molecules
during the course of ES cell in vitro differentiation. While
we are progressing toward discovering new soluble rea-
gents, genetic based programming provides an important
tool to decipher the pathways and mechanisms control-
ling stem cell fate choice which is fundamental for the
establishment of culture parameters capable of sustaining
the full complement of NSC potential. Furthermore, the
timely investment in iPS related studies should prompt
rapid technological developments such as protein trans-
duction or small molecule mediated gene regulation.
Summary
The past few years have seen a rapid progress in our under-
standing in the genetic control of mDA neuron fate speci-
fication during foetal development. Combinatorial
expression of transcription regulators provides markers
for ventral mesencephalic neuroepithelial cells of differ-
ent regional zones and/or at different developmental
stages. These mDA neuron lineage markers have greatly
facilitated the assessment of 'authentic' mDA neural phe-
notype that can be derived from ES cells. In addition, the
availability of defined mDA neuron progenitor popula-
tions with distinct differentiation capacity isolated by lin-
eage marker expression from existing reporter mice and ES
cells has initiated the search for the most suitable cell pop-
ulation for cell-based transplantation therapy [77,90].
Most importantly, knowledge of intrinsic and extrinsic
mDA neuron developmental cues has been successfully
translated into novel strategies for mDA neuron produc-
tion in vitro from ES cells. Combining enhanced effi-
ciency of generating mDA neurons in vitro with the use of
reporter ES cell lines that track mDA neuron precursors of
different developmental stages, the ES cell based differen-
tiation assays offer a simplified model system in which to
dissect the interactions of intrinsic and extrinsic signals
controlling mDA neuron specification. DA neurons gener-
ated from iPS cells, especially those harbouring Parkin-
son's disease mutations, provide a potential tool to study
the disease process and to test the efficacy of preventative
or therapeutic drugs. Even though great progress has been
made, our understanding of the genetic cues controlling
the induction of the mDA neuron progenitors and the
specification of the mDA neuronal fate is far from com-
plete. Further advances in the field will undoubtedly facil-
itate the controlled differentiation of pluripotent stem
cells into clinically relevant DA neurons.
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